Abstract shows ovarian cancer data for Lilly's mAb against VEGFR-2

Ramucirumab, a mAb against VEGFR-2 from Eli Lilly and Co. (NYSE:LLY), led to a 34% progression-free survival rate at six months in a Phase II trial in 60 ovarian cancer patients, according to an abstr...